JP2014529614A5 - - Google Patents

Download PDF

Info

Publication number
JP2014529614A5
JP2014529614A5 JP2014527498A JP2014527498A JP2014529614A5 JP 2014529614 A5 JP2014529614 A5 JP 2014529614A5 JP 2014527498 A JP2014527498 A JP 2014527498A JP 2014527498 A JP2014527498 A JP 2014527498A JP 2014529614 A5 JP2014529614 A5 JP 2014529614A5
Authority
JP
Japan
Prior art keywords
composition
use according
administered
csf
homologue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014527498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014529614A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014529614A publication Critical patent/JP2014529614A/ja
Publication of JP2014529614A5 publication Critical patent/JP2014529614A5/ja
Pending legal-status Critical Current

Links

JP2014527498A 2011-08-29 2012-08-29 放射線により誘発されるまたは化学療法により誘発される肺機能不全の治療または予防のための組成物および方法 Pending JP2014529614A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161528459P 2011-08-29 2011-08-29
US61/528,459 2011-08-29

Publications (2)

Publication Number Publication Date
JP2014529614A JP2014529614A (ja) 2014-11-13
JP2014529614A5 true JP2014529614A5 (enExample) 2015-10-29

Family

ID=46888859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014527498A Pending JP2014529614A (ja) 2011-08-29 2012-08-29 放射線により誘発されるまたは化学療法により誘発される肺機能不全の治療または予防のための組成物および方法

Country Status (5)

Country Link
US (3) US20140205658A1 (enExample)
EP (1) EP2750696A1 (enExample)
JP (1) JP2014529614A (enExample)
RU (1) RU2014111818A (enExample)
WO (1) WO2013029627A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014341862A1 (en) 2013-11-04 2016-05-19 Board Of Regents, The University Of Texas System Compositions and methods for administration of an enzyme to a subject's airway
WO2015110536A1 (en) * 2014-01-22 2015-07-30 Reponex Pharmaceuticals Aps Granulocyte-macrophage colony-stimulating factor for the treatment and prevention of severe forms of bronchial asthma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP2010508365A (ja) * 2006-11-03 2010-03-18 ダラグレキュル・アンパルトセルスカブ 顆粒球マクロファージコロニー刺激因子を投与することによる肺の宿主防御の増強
WO2008109818A1 (en) * 2007-03-07 2008-09-12 Mayo Foundation For Medical Education And Research Treating cancer with granulocyte-macrophage colony stimulating factor

Similar Documents

Publication Publication Date Title
JP2010508365A5 (enExample)
JP2014028839A5 (enExample)
Velkov et al. Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead
MX2009004802A (es) Incremento de las defensas pulmonares del hospedero mediante la administracion del factor estimulador de colonias de granulositos-macrofagos.
JP2016513688A5 (enExample)
IN2014DN08672A (enExample)
CL2009000601A1 (es) Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclinio equivalente a aproximadamente 200 ug de bromuro de aclinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis.
JP2013540123A5 (enExample)
IN2014DN11257A (enExample)
JP2018528966A5 (enExample)
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
Safdar et al. Inhaled therapeutics for prevention and treatment of pneumonia
JP2014529614A5 (enExample)
RU2014111818A (ru) Композиции и способы для лечения или предупреждения легочной дисфункции, вызываемой лучевой терапией или химиотерапией
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
MY187442A (en) A pharmaceutical composition containing budesonide and formoterol
WO2015066664A3 (en) Compositions and methods for administration of an enzyme to a subject's airway
JP2016535782A5 (enExample)
JP2013522295A5 (enExample)
Kuzovlev et al. Inhaled antibiotics in treatment of nosocomial pneumonia
TW Clarke et al. Targeted drug delivery to the virus-infected airway; complications and remedies
BR112015004810A2 (pt) preparações de tiotrópio
Miwata et al. Vascular Endothelial Growth Factor Knockdown by Intratracheal Administration of Small-Interfering RNA Dry Powder Inhibits Tumor Growth in a Mouse Lung Metastasis Model
MY191295A (en) Pharmaceutical composition containing budesonide and formoterol
von Hollen et al. In vitro comparison of aerosol characteristics of three HFA pressurized metered dose inhaler formulations commonly used in asthma using two valved holding chambers